Skip to Main Content

Paper Details

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.
Nat Commun
0
2022
CDK4/6, ER, ER breast cancer, RB1, p16
Author NameAffiliation
Abel Gonzalez-PerezInstitute for Research in Biomedicine (IRB Barcelona)
Abel Gonzalez-PerezUniversitat Pompeu Fabra
Alejandra BrunaPreclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research
Carlos Caldas
Rodrigo DienstmannVall d'Hebron Institute of Oncology
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona)
Nuria Lopez-BigasUniversitat Pompeu Fabra
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona)
Nuria Lopez-BigasUniversitat Pompeu Fabra
Nuria Lopez-BigasInstitucio Catalana de Recerca i Estudis Avancats (ICREA)
  • 1 - 11

Datasets

Release 1.2